At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
Azithromycin plus chloroquinedrug
Likely dose
Azithromycin plus chloroquine 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open Label, Non-Comparative Trial Of Azithromycin 2000 mg Plus Chloroquine 600 Mg Base Daily For Three Days For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria
In Brief
A Phase 2 clinical trial evaluating Azithromycin plus chloroquine for Falciparum Malaria. Completed, enrolled 110 participants across 2 sites in 2 countries.
Detailed Summary
The treatment of symptomatic, uncomplicated malaria caused by P. falciparum in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFalciparum Malaria
CountriesColombia, India
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2006
Enrollment StartMar 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedJan 27, 2006
Enrollment StartMar 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.4 years ago
Interventions
Azithromycin plus chloroquinedrug
dose of 2000 mg Azithromycin plus 600 mg chloroquine base